Catalyst
Slingshot members are tracking this event:
AbbVie (ABBV) Announces Top-Line Data from Phase 3 CERTAIN-1 Study Evaluating Ribavirin-Free Regimen of Glecaprevir and Pibrentasvir (G/P) in Japanese Patients with Genotype 1 Chronic Hepatitis C virus (HCV) Infection Without Cirrhosis
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 09, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Top-line, Phase 3 Certain-1, Ribavirin-free, Glecaprevir, Pibrentasvir, Japanese Patients, Genotype 1 Chronic Hepatitis C Virus, Cirrhosis
